Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 102 Records) |
| Query Trace: Disease and MUT[original query] |
|---|
| Drug resistance pattern and mutation pattern in pediatric tuberculosis: Study from north India. The Indian journal of tuberculosis 2021 11 68 (4): 481-484. Khurana Prerna, Saigal Karnika, Ghosh Arn |
| Genomic Landscape in Neoplasm-Like Stroma Reveals Distinct Prognostic Subtypes of Pancreatic Ductal Adenocarcinoma. Frontiers in oncology 2021 11 11 771247. Jiang Jiahong, Xu Yaping, Chang Lianpeng, Ru Guoqing, Xia Xuefeng, Yang Ling, Yi Xin, Chen Zheling, Huang Dong-Sheng, Yang L |
| TET-2 mutations predict poor outcomes and are associated with unfavorable clinical-biological features in PTCL, not otherwise specified and angioimmunoblastic T-cell lymphoma in Brazilian patients. Cancer biomarkers : section A of Disease markers 2022 Sep . de Pádua Covas Lage Luís Alberto, Barreto Guilherme Carneiro, Culler Hebert Fabricio, Cavalcante Jéssica Billar, de Oliveira Alves Lucas Bassolli, Nardinelli Luciana, Bendit Israel, Zerbini Maria Cláudia Nogueira, Rocha Vanderson, Pereira Julia |
| A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11). Clinical cancer research : an official journal of the American Association for Cancer Research 2022 7 28 (19): 4240-4247. Jung Hyun Ae, Park Keon-Uk, Cho Sanghee, Lim Jinyeong, Lee Keun-Wook, Hong Min Hee, Yun Tak, An Ho Jung, Park Woong-Yang, Pereira Sergio, Ock Chan-Young, Keam Bhums |
| Prognostic significance of PD-L1 expression and CD8 TILs density for disease-free survival in surgically resected lung squamous cell carcinoma: a retrospective study. Journal of thoracic disease 2022 7 14 (6): 2224-2234. Cheng Xiaomin, Wang Lei, Zhang Zhem |
| Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. ESMO open 2022 6 7 (3): 100506. Boccaccino A, Borelli B, Intini R, Antista M, Bensi M, Rossini D, Passardi A, Tamberi S, Giampieri R, Antonuzzo L, Noto L, Roviello G, Zichi C, Salati M, Puccini A, Noto C, Parisi A, Rihawi K, Persano M, Crespi V, Libertini M, Giordano M, Moretto R, Lonardi S, Cremolini |
| PIK3CA Gene Mutations in HNSCC: Systematic Review and Correlations with HPV Status and Patient Survival. Cancers 2022 3 14 (5): . Cochicho Daniela, Esteves Susana, Rito Miguel, Silva Fernanda, Martins Luís, Montalvão Pedro, Cunha Mário, Magalhães Miguel, Gil da Costa Rui M, Felix A |
| Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy. Therapeutic advances in medical oncology 2022 12 14 17588359221141761. Lee Jii Bum, Park Hyung Soon, Choi Su Jin, Heo Seong Gu, An Ho Jung, Kim Hye Ryun, Hong Min Hee, Lim Sun Min, Chang Kyle, Quinn Katie, Odegaard Justin, Shim Byoung Yong, Cho Byoung Ch |
| Lipase-a single-nucleotide polymorphism rs143793106 is associated with increased risk of aggressive periodontitis by negative influence on the cytodifferentiation of human periodontal ligament cells. Journal of periodontal research 2022 12 58 (1): 175-183. Matsumoto Masahiro, Fujihara Chiharu, Nantakeeratipat Teerachate, Kitagaki Jirouta, Yamamoto Yu, Yamada Satoru, Kitamura Masahiro, Murakami Shin |
| High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. Journal of hematology & oncology 2022 01 15 (1): 9. Cortellini Alessio, Giusti Raffaele, Filetti Marco, Citarella Fabrizio, Adamo Vincenzo, Santini Daniele, Buti Sebastiano, Nigro Olga, Cantini Luca, Di Maio Massimo, Aerts Joachim G J V, Bria Emilio, Bertolini Federica, Ferrara Miriam Grazia, Ghidini Michele, Grossi Francesco, Guida Annalisa, Berardi Rossana, Morabito Alessandro, Genova Carlo, Mazzoni Francesca, Antonuzzo Lorenzo, Gelibter Alain, Marchetti Paolo, Chiari Rita, Macerelli Marianna, Rastelli Francesca, Della Gravara Luigi, Gori Stefania, Tuzi Alessandro, De Tursi Michele, Di Marino Pietro, Mansueto Giovanni, Pecci Federica, Zoratto Federica, Ricciardi Serena, Migliorino Maria Rita, Passiglia Francesco, Metro Giulio, Spinelli Gian Paolo, Banna Giuseppe L, Friedlaender Alex, Addeo Alfredo, Ficorella Corrado, Porzio Giampiero, Tiseo Marcello, Russano Marco, Russo Alessandro, Pinato David Jam |
| Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric Thyroid Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 1 40 (10): 1081-1090. Franco Aime T, Ricarte-Filho Julio C, Isaza Amber, Jones Zachary, Jain Neil, Mostoufi-Moab Sogol, Surrey Lea, Laetsch Theodore W, Li Marilyn M, DeHart Jessica Clague, Reichenberger Erin, Taylor Deanne, Kazahaya Ken, Adzick N Scott, Bauer Andrew |
| Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer 2022 Jun . Cortellini Alessio, Ricciuti Biagio, Borghaei Hossein, Naqash Abdul Rafeh, D'Alessio Antonio, Fulgenzi Claudia A M, Addeo Alfredo, Banna Giuseppe L, Pinato David Jam |
| Establishment and validation of an immune infiltration predictive model for ovarian cancer. BMC medical genomics 2023 9 16 (1): 227. Zhenxia Song, Jingwen Zhang, Yue Sun, Zhongmin Jiang, Xiaoning L |
| Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma. Frontiers in oncology 2023 7 13 1169586. Prashanth Ashok Kumar, Serenella Serinelli, Daniel J Zaccarini, Richard Huang, Natalie Danziger, Tyler Janovitz, Alina Basnet, Abirami Sivapiragasam, Stephen Graziano, Jeffrey S Ro |
| Genetic mutations in smoking-associated prostate cancer. The Prostate 2023 7 . Ahmed Elshafei, Mohammed Al-Toubat, Allison H Feibus, Kashyap Koul, Seyed Behzad Jazayeri, Navid Lelani, Valencia Henry, K C Bala |
| Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome. Hematology (Amsterdam, Netherlands) 2023 6 28 (1): 2220222. Yue Feng, Haiping Liang, Meining Han, Xingchun Luo, Yu Zhu, Bei L |
| Comparative analysis of adjuvant therapy for stage III BRAF-mut melanoma: A real-world retrospective study from single center in China. Cancer medicine 2023 4 . Zhong Jingqin, Sun Wei, Hu Tu, Wang Chunmeng, Yan Wangjun, Luo Zhiguo, Liu Xin, Xu Yu, Chen Yo |
| Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. European journal of cancer (Oxford, England : 1990) 2023 4 187 15-24. Paolo Manca, Francesca Corti, Rossana Intini, Giacomo Mazzoli, Rosalba Miceli, Marco Maria Germani, Francesca Bergamo, Margherita Ambrosini, Eleonora Cristarella, Riccardo Cerantola, Chiara Boccaccio, Gianmarco Ricagno, Filippo Ghelardi, Giovanni Randon, Giuseppe Leoncini, Massimo Milione, Matteo Fassan, Chiara Cremolini, Sara Lonardi, Filippo Pietranton |
| Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer. Oncology (Williston Park, N.Y.) 2023 12 37 (12): 488-495. Suneel Kamath, Joanna Roopkumar, Ying Ni, Minqian Shen, Pablo Bejarano, Daniela Allende, Arun Nagarajan, Tim Nguyen, Bachar Dergham, Dale Shepard, Marc A Shapiro, Michael J McNamara, Bassam N Estfan, Kanika G Nair, Alok A Khora |
| Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB. Journal for immunotherapy of cancer 2023 11 11 (11): . Jie He, Natallia Kalinava, Parul Doshi, Dean C Pavlick, Lee A Albacker, Ericka M Ebot, Hanna Tukachinsky, James Pratt, Gina Fusaro, Geoffrey R Oxnard, George Green, David Fabrizio, Jonathan Bad |
| Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis. Urologic oncology 2023 10 . Mohammed Al-Toubat, Samuel Serrano, Ahmed Elshafei, Kashyap Koul, Allison H Feibus, K C Bala |
| Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology. Frontiers in oncology 2023 1 12 1092201. Valentini Virginia, Silvestri Valentina, Bucalo Agostino, Conti Giulia, Karimi Mina, Di Francesco Linda, Pomati Giulia, Mezi Silvia, Cerbelli Bruna, Pignataro Maria Gemma, Nicolussi Arianna, Coppa Anna, D'Amati Giulia, Giannini Giuseppe, Ottini Lau |
| Clinical features and prognostic biomarkers in patients with SMARCA4-mutated non-small cell lung cancer. Translational lung cancer research 2024 9 13 (8): 1938-1949. Jinyu Long, Ying Chen, Xingguang Luo, Ruiying Rao, Chenxi Wang, Yuxin Guo, Jinhe Xu, Ping Lin, Yingfang Song, Lijuan Qu, Qinghong Liu, Jun Lu, Chengzhi Zhou, Zhengbo Song, Xiandong Lin, Hiroyuki Adachi, Jacek Jassem, Masatsugu Hamaji, Zongyang |
| Molecular and Clinicopathologic Impact of GNAS Variants Across Solid Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 8 JCO2400186. Paul Johannet, Somer Abdelfattah, Callahan Wilde, Shrey Patel, Henry Walch, Benoit Rousseau, Guillem Argiles, Oliver Artz, Miteshkumar Patel, Andrea Arfe, Andrea Cercek, Rona Yaeger, Karuna Ganesh, Nikolaus Schultz, Luis A Diaz, Michael B Foo |
| Clinical outcomes of patients with mut-type methylmalonic acidemia identified through expanded newborn screening in China. Human genomics 2024 7 18 (1): 84. Shiying Ling, Shengnan Wu, Ruixue Shuai, Yue Yu, Wenjuan Qiu, Haiyan Wei, Chiju Yang, Peng Xu, Hui Zou, Jizhen Feng, Tingting Niu, Haili Hu, Huiwen Zhang, Lili Liang, Yu Wang, Ting Chen, Feng Xu, Xuefan Gu, Lianshu H |
| Pan-cancer analysis of CDKN2A alterations identifies a subset of gastric cancer with a cold tumor immune microenvironment. Human genomics 2024 6 18 (1): 55. Chao Deng, Zi-Xi Li, Chen-Jun Xie, Qing-Lin Zhang, Ben-Shun Hu, Mei-Dan Wang, Jie Mei, Chen Yang, Zhangfeng Zhong, Ke-Wei Wa |
| The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab. ESMO open 2024 5 9 (5): 102964. L Buisseret, Y Bareche, D Venet, E Girard, A Gombos, P Emonts, S Majjaj, G Rouas, M Serra, V Debien, E Agostinetto, S Garaud, K Willard-Gallo, D Larsimont, J Stagg, F Rothé, C Sotiri |
| Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2024 5 . M Ambrosini, B Rousseau, P Manca, O Artz, A Marabelle, T André, G Maddalena, G Mazzoli, R Intini, R Cohen, A Cercek, N H Segal, L Saltz, A M Varghese, R Yaeger, M Nusrat, Z Goldberg, G Y Ku, I El Dika, O Margalit, A Grinshpun, P Kasi, R Schilsky, A Lutfi, E Shacham-Shmueli, M Khan Afghan, L Weiss, C B Westphalen, V Conca, B Decker, G Randon, E Elez, M Fakih, A B Schrock, C Cremolini, P Jayachandran, M J Overman, S Lonardi, F Pietranton |
| Integrated profile of tumor stage and mutational burden predicts disparate clinical responses to immune checkpoint inhibitors: A risk-benefit study. Seminars in oncology 2024 11 . Ming Zhe |
| Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2024 1 . Min-Min Shao, Yue-Ping Xu, Jin-Jing Zhang, Mao Mao, Meng-Chuan Wa |
- Page last reviewed:Feb 1, 2024
- Content source: